|Articles|April 28, 2022

Introducing Liquid Single-Use Bags from ILC Dover

Author(s)ILC Dover

ILC Dover announced its launch of liquid single-use bioprocessing bags, representing the first of many new products for handling sterile liquids in the biotherapeutics and cell and gene therapy markets. This expansion continues our line of solutions designed for use across the entire biotherapeutic and pharmaceutical manufacturing workflow—from powder containment and handling to sterile liquid handling and pre-filled liquid and powder bags.


Related to this article

The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.